Regeneron Pharmaceuticals, Inc.
REGN Healthcare Biotechnology
Regeneron Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, up 0.99% from fiscal 2024. In the quarter to June 2026, revenue grew 16.7%, EPS fell 4.68%, free cash flow fell 29.3% and total debt fell 26.6%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for three consecutive years.
Follow REGN
Regeneron Pharmaceuticals, Inc. (REGN) Dividend Safety Score
Regeneron Pharmaceuticals, Inc.'s stockrow Dividend Safety Score is 77 out of 100, based on payout ratios, leverage, dividend streak and earnings stability for fiscal 2025.
Dividend Safety Score, annual
Embed this chart
Annual newest first
| Period | Dividend Safety Score | Change (points) |
|---|---|---|
| FY2025 | 77 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Payout of earnings | 8.22% | — | Pass | 25 |
| Payout of free cash flow | 9.83% | — | Pass | 25 |
| Net debt / EBITDA net cash | — | — | Pass | 20 |
| Years without a dividend cut | 0 | — | Fail | 0 |
| Years of falling or negative earnings over the last 10 fiscal years | 1 | — | Fail | 7 |
| Dividend Safety Score | Adequately covered | 77 | ||
How the stockrow Dividend Safety Score works
Our own composite, out of 100, for the latest fiscal year: up to 25 points for how little of its earnings the dividend takes, 25 for how little of its free cash flow, 20 for net debt against EBITDA, 20 for the years it has paid without a cut and 10 for how steady earnings per share have been over ten years. How we calculate it.
| 80–100 | Well covered |
|---|---|
| 60–79 | Adequately covered |
| 40–59 | Stretched |
| below 40 | Weakly covered |
Not worked out for a company that pays no regular dividend, for banks and REITs, whose payouts and leverage these measures do not describe, or with fewer than five years of earnings.
Dividend Safety Score against peers
| Company | Dividend Safety Score |
|---|---|
| REGN Regeneron Pharmaceuticals, Inc. | 77 |
| RPRX Royalty Pharma PLC compare | 37 |
| ROIV Roivant Sciences Ltd. compare | — |
| VRTX Vertex Pharmaceuticals Incorporated compare | — |
| ARGX argenex SE compare | — |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | — |
| MRNA Moderna, Inc. compare | — |
| ALNY Alnylam Pharmaceuticals, Inc. compare | — |
| RVMD Revolution Medicines, Inc. compare | — |
What Dividend Safety Score is
The stockrow Dividend Safety Score rates how well earnings and free cash flow cover the dividend, with leverage, the dividend’s record and stable earnings.
Up to 25 points for the payout of earnings, 25 for the payout of free cash flow, 20 for net debt ÷ EBITDA, 20 for the years without a dividend cut and 10 for stable earnings
More on REGN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement